Cabozantinib, an inhibitor targeting VEGF, c-MET, and AXL, exhibits potent inhibitory effects, inducing mitotic catastrophe and apoptosis in radiation and cisplatin-resistant HNSCC cells (71). Here, AXL is linked to head and neck squamous cell carcinoma.